secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037982
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector reports Q2 net income $1.4M, cash $630M; updates clinical trial timelines
--------------------------------------------------------------------------------

- Q2 2023 revenue $56.2M (down 30% YoY); net income $0.02 EPS vs $0.12 EPS in Q2 2022.
- Cash, equivalents & investments $630M, expected to fund operations through 2025.
- Guidance updated: 2023 collaboration revenue $90-100M (up), R&D $210-220M (down), G&A $60-65M.
- Invoke-2 Phase 2 (AL002) enrollment completion Q3 2023; data readout Q4 2024.
- INFRONT-3 pivotal trial enrollment completion expected Q4 2023; primary analysis on ~90-100 symptomatic FTD-GRN participants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/0000950170-23-037982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/alec-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer